CLINICAL_TRIALS
trial_result
· 2010-03-08
Clinical Trial Update: ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH) [Phase 3]
Summary
Phase 3 trial update on ambrisentan (Letairis) in adults with moderate to severe pulmonary arterial hypertension has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Gilead Sciences | Conditions: Pulmonary Hypertension | Phase 3 | Status: COMPLETED